Eledon Pharmaceuticals, Inc.
ELDN
$1.59
$0.117.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.55M | 19.44M | 19.28M | 18.31M | 14.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.46M | 87.90M | 77.67M | 70.58M | 56.22M |
| Operating Income | -86.46M | -87.90M | -77.67M | -70.58M | -56.22M |
| Income Before Tax | -79.36M | 15.07M | -18.62M | -35.75M | -21.67M |
| Income Tax Expenses | 431.00K | 431.00K | 431.00K | 431.00K | -- |
| Earnings from Continuing Operations | -79.79 | 14.64 | -19.05 | -36.18 | -21.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.79M | 14.64M | -19.05M | -36.18M | -21.67M |
| EBIT | -86.46M | -87.90M | -77.67M | -70.58M | -56.22M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.05 | 1.08 | -0.29 | -0.99 | -1.39 |
| Normalized Basic EPS | -0.68 | 0.39 | -0.18 | -0.62 | -0.85 |
| EPS Diluted | -1.05 | -1.11 | -2.48 | -3.18 | -3.59 |
| Normalized Diluted EPS | -0.68 | 0.33 | -0.24 | -0.68 | -0.91 |
| Average Basic Shares Outstanding | 301.40M | 276.19M | 241.66M | 194.52M | 154.71M |
| Average Diluted Shares Outstanding | 301.40M | 279.72M | 245.19M | 198.05M | 158.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |